siRNA News and Research

RSS
Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, is a class of double-stranded RNA molecules, 20-25 nucleotides in length, that play a variety of roles in biology. Most notably, siRNA is involved in the RNA interference (RNAi) pathway, where it interferes with the expression of a specific gene. In addition to their role in the RNAi pathway, siRNAs also act in RNAi-related pathways, e.g., as an antiviral mechanism or in shaping the chromatin structure of a genome; the complexity of these pathways is only now being elucidated.
Alnylam releases positive top-line data from ALN-TTRsc Phase I trial for TTR-mediated amyloidosis

Alnylam releases positive top-line data from ALN-TTRsc Phase I trial for TTR-mediated amyloidosis

New approach delivers RNA drugs to silence malfunctioning genes

New approach delivers RNA drugs to silence malfunctioning genes

Alnylam Pharmaceuticals presents new pre-clinical data of ALN-AT3 at ISTH meeting

Alnylam Pharmaceuticals presents new pre-clinical data of ALN-AT3 at ISTH meeting

Study suggests new ways to maximize delivery of RNA strands

Study suggests new ways to maximize delivery of RNA strands

Researchers provide new revelations about intricate pathways involved in turning on T cells

Researchers provide new revelations about intricate pathways involved in turning on T cells

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

Bioapplications of nanoparticles: an interview with Dr Catherine Berry, University of Glasgow

Bioapplications of nanoparticles: an interview with Dr Catherine Berry, University of Glasgow

Arcturus Therapeutics closes $1.3 M in seed funding round

Arcturus Therapeutics closes $1.3 M in seed funding round

New drug delivery system can help treat lung cancer

New drug delivery system can help treat lung cancer

Alnylam reports pre-clinical data from ALN-AS1 program for treatment of AIP

Alnylam reports pre-clinical data from ALN-AS1 program for treatment of AIP

Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

Wistar researchers find surprising role for RNA-editing protein in gene silencing

Wistar researchers find surprising role for RNA-editing protein in gene silencing

Santaris Pharma, Bristol-Myers Squibb partner to develop novel medicines using LNA Drug Platform

Santaris Pharma, Bristol-Myers Squibb partner to develop novel medicines using LNA Drug Platform

University of Alberta researcher develops polymer platform technology for targeted drug delivery

University of Alberta researcher develops polymer platform technology for targeted drug delivery

Novel nanoparticle-based approach enables more efficient delivery of siRNA drugs

Novel nanoparticle-based approach enables more efficient delivery of siRNA drugs

Cellectis CanCELL cell lines enable drug positioning in cancer pathways

Cellectis CanCELL cell lines enable drug positioning in cancer pathways

Study shows cholesterol rafts can shepherd genetic payloads into cancer cells

Study shows cholesterol rafts can shepherd genetic payloads into cancer cells

Alnylam begins dosing in Phase I clinical trial with ALN-TTRsc for treatment of ATTR

Alnylam begins dosing in Phase I clinical trial with ALN-TTRsc for treatment of ATTR

New drug delivery system can reduce size of ovarian tumors by as much as 83%

New drug delivery system can reduce size of ovarian tumors by as much as 83%